✦Canada Post Xpress1–2 day delivery across CanadaFree on orders over $200
Your cart is empty
Non-Erythropoietic EPO Analogue
Also known as Cibinetide
ARA-290 (cibinetide) is a synthetic 11–amino acid peptide engineered from the structure of erythropoietin, studied in research for tissue-protective signaling without erythropoietic activity.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
ARA-290 (cibinetide) is a synthetic 11–amino acid peptide engineered from the structure of erythropoietin, studied in research for tissue-protective signaling without erythropoietic activity.
Experimental models examine its interaction with the innate repair receptor in inflammatory and neuropathic-pain frameworks.
Third-party tested for purity, ID, quantity.
ARA-290 is a peptide derived from a region of erythropoietin responsible for tissue protection, designed to engage the innate repair receptor while avoiding the hematopoietic effects of EPO. Research has examined its anti-inflammatory and neuroprotective behavior.
Studies span small-fiber neuropathy, metabolic, and immune-modulation research models under structured conditions.
ARA-290 emerged from research separating erythropoietin’s tissue-protective signaling from its erythropoietic activity. The engineered peptide was characterized to retain cytoprotection without raising red-cell mass.
Subsequent clinical and preclinical work investigated neuropathic-pain and metabolic-control endpoints.
Research into ARA-290 focuses on innate-repair-receptor signaling and tissue-protective models. Frameworks evaluate anti-inflammatory activity, neuropathic-pain endpoints, and metabolic regulation under controlled clinical and preclinical conditions.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of ara 290. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
PubMedA Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets
PubMedRelated
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$70.00
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$50.00
Immune-modulating peptide studied for T-cell signaling and immune system regulatory pathway research
From$60.00
GHRH analog studied for growth hormone regulation and metabolic pathway signaling research
From$90.00
